developed for the clinical treatment of insulin-resistant DM. 7 In addition to reducing insulin resistance, pioglitazone increases plasma adiponectin levels, which have a pivotal role in the development of DM, metabolic syndrome, and even in the progression to CAD. 5, 8 Recently, the PROactive Study established a specific role for pioglitazone in the secondary prevention of macrovascular events in patients with type 2 DM. 9 The PERISCOPE Trial revealed that treatment with pioglitazone resulted in a significant reduction of coronary plaque volume compared with glimepiride, 10 and Sugamura et al reported that pioglitazone treatment improved carotid plaque components in patients with statin treated nondiabetic CAD. 11 Thus, pioglitazone may have a beneficial effect on coronary plaque, but none of the previous studies clarified whether pioglitazone has a definite antiatherogenic effect on coronary plaque components.
Virtual histology (VH) intravascular ultrasound (IVUS), which uses amplitude and frequency analysis of the IVUS backscatter signals, can reliably identify atherosclerotic plaque components. 12 The reconstructed color-coded tissue maps with 4 different types of atherosclerotic plaques have high in-vitro predictive accuracy. 13, 14 This new imaging modality makes it possible to characterize the coronary plaque tissue changes associated with long-term pharmaceutical treatment, so we used it to investigate the effect of pioglitazone on coronary plaque volume and components in association with the change in serum biomarkers in patients with stable angina pectoris (AP) and type 2 DM.
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Methods
Patients and Study Design
This study was a prospective, single-center, randomized, open trial of pioglitazone therapy versus control. We enrolled 54 patients with type 2 DM and stable AP, who were scheduled for percutaneous coronary intervention (PCI) and 6-month follow-up angiography. For the diagnosis of DM, we adopted the following criteria established by the World Health Organization and American Diabetes Association: fasting glucose >126 mg/dl (7.0 mmol/L) or 2-h blood glucose >200 mg/dl (11.1 mmol/L). All study subjects were randomly assigned to the pioglitazone group (n=27) or the control group (n=27). The pioglitazone group received 15 mg/day pioglitazone in addition to their existing medications for DM, while the control group continued with their previous antidiabetic regimen. Patients with significant hepatic or renal disease, congestive heart failure (New York Heart Association functional class II-IV), or systemic inflammatory disorders (collagen disease, malignancy, infectious disease etc) were excluded to avoid their influence on biomarker levels. Other medical treatments remained unchanged throughout the study. The primary end-point of the study was the change in plasma adiponectin levels and the change in each VH-IVUS parameter from baseline to follow-up. A secondary end-point was the correlation between the change in serum biomarkers and the change in each VH-IVUS parameter. The study protocol was approved by the Ethics Committee of Kobe University and all participants provided written informed consent prior to their participation in the study.
Laboratory Studies
At study entry and at the 6-month follow-up, blood samples were obtained in the early morning after overnight fasting and immediately centrifuged for 10 min at 3,000 rpm and stored at -70°C until analysis. Total cholesterol and triglycerides were measured using the enzymatic method. Low-density lipoprotein (LDL)-cholesterol and high-density lipoprotein (HDL)-cholesterol were measured using the selective solubilization method and modified enzymatic method, respectively (Kyowa Medex Co Ltd, Tokyo, Japan). Fasting glucose was determined with the hexokinase method and glycosylated hemoglobin (HbA1c) with cation-exchange high-performance liquid chromatography. High-sensitivity (hs) C-reactive protein (CRP) levels were measured using an ultrasensitive CRP test with a coefficient of variation of less than 5% (N Latex CRP; Dade Behring Co Ltd, West Sacramento, CA, USA), and plasma adiponectin concentration with an enzyme-linked immunosorbent assay with a coefficient of variation of less than 5% (Otsuka Pharmaceutical Co Ltd, Tokyo, Japan). Fasting immunoreactive insulin (IRI) was determined with the fully automated enzyme immunoassay analyzer system AIA-21 (Tosoh Corporation, Tokyo, Japan), and insulin resistance was estimated using the following homeostasis model to assess insulin resistance (HOMA-IR): fasting plasma glucose (mmol/L) × IRI (μU/ml)/22.5.
IVUS and VH-IVUS Analysis
After successful treatment of the culprit lesion with PCI, the PCI-related coronary vessel was subjected to VH-IVUS examination after administration of 0.4 mg isosorbide dinitrate into the coronary artery. IVUS catheters were commercially-available phased array catheters (Eagle Eye Gold™ 2.9F 20-MHz; Volcano Corp, Rancho Cordova, CA, USA). The region of interest (ROI) for IVUS measurements was defined as a non-culprit, de novo, angiographically mild-tomoderate obstructive focal site (25-75% stenosis) of the PCI-related vessel. The selected ROI was at least 10 mm away from the PCI target area to avoid the influence of PCI treatment, and the location of the ROI was identified by the distance from an identifiable side branch, ostium or the edge of the implanted stent. The IVUS catheter tip was placed at least 10 mm distal to the ROI, and pulled back at least 10 mm proximal to the ROI at a continuous speed of 0.5 mm/s using a motorized pullback device. Acquired gray-scale IVUS images were stored on a CD-ROM and raw radiofrequency signals were stored on a DVD for off-line analysis (Volcano Corp). Atherosclerotic coronary plaque was characterized using classification trees based on mathematical autoregressive spectral analysis of the IVUS backscattered data (IVUSLab software, Volcano Corp). Constructed tissue maps were classified into the 4 major components with the aid of IVUSLab software (version 2.0), and the components were assigned different color codes: dark green for Fibrous, light green for Fibro-fatty, white for Dense-calcium, and red for Necrotic-core. Plaque area was defined as the external elastic membrane area minus the lumen area. For every slice, the plaque area and area of each plaque component on the tissue map was calculated automatically by the IVUSLab software, followed by calculation of the individual volumetric data for each component by the same software using the trapezoidal method. The %Plaque volume was defined as the ratio of plaque volume to external elastic membrane volume and each plaque component was represented as a ratio of the total plaque volume (%Fibrous, %Fibro-fatty, %Dense-calcium, and %Necrotic-core). At the 6-month follow-up angiography, VH-IVUS analysis was used to examine the same matched lesions in the same manner as before, followed by calculation of the change from baseline to the 
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6-month follow-up in each of the VH-IVUS parameters (Fig 1) . The analysis of VH-IVUS data was performed by skilled reviewers who were unaware of the treatment assignment. For the preliminary VH-IVUS study, we also evaluated the inter-observer and inter-catheter variabilities for each of the histologic parameters. Thirty randomly selected non-culprit lesions were measured once and independently by 2 skilled IVUS researchers and twice using 2 IVUS catheters.
Statistical Analysis
Discrete variables are presented as counts or percentages, and continuous variables as mean ± SD. Absolute change from baseline for each of the variables was obtained as the difference between the baseline and follow-up values. Categorical variables were analyzed with the chi-square test and continuous variables with the 2-sided Student's t-test. The paired t-test was used for intra-group comparisons of the laboratory and VH-IVUS parameters, and the unpaired t-test for inter-group comparisons. The inter-observer and intercatheter correlations and the correlation between the change in the plasma adiponectin level and the change in each of the histologic VH-IVUS parameters were assessed using Pearson's correlation coefficient. Inter-observer and intercatheter agreements were also evaluated on Bland-Altman plots, and the limits of agreement were determined by the mean difference between data obtained with the 2 techniques ± 2SD. A 2-sided P-value <0.05 was considered statistically significant. All statistical analyses were performed using MedCalc software version-9.2 for Windows (MedCalc, Mariakerke, Belgium).
Results
Reproducibility of VH-IVUS Histologic Data
Inter-observer correlations for the absolute volume of the histologic parameters were r=0.96 for Fibrous, P<0.0001; r=0.96 for Fibro-fatty, P<0.0001; r=0.99 for Dense-calcium, P<0.0001; and r=0.99 for Necrotic-core, P<0.0001. Intercatheter correlations for the absolute volume of the histologic parameters were r=0.98 for Fibrous, P<0.0001; r=0.86 for Fibro-fatty, P<0.0001; r=0.98 for Dense-calcium, P< 0.0001; and r=0.91 for Necrotic-core, P<0.0001. The BlandAltman plots for inter-observer and inter-catheter variabilities in the histologic data are shown in Fig 2. Among these, the inter-observer variabilities for the Necrotic-core were 2.1 mm 3 and -1.1 mm 3 for 2SD, and respective inter-catheter variabilities were 6.4 mm 3 and -5.7 mm 3 for 2SD.
Patient Characteristics
In the pioglitazone group, 1 patient withdrew consent, 2 were lost to follow-up, and 2 were excluded because of insufficient IVUS images caused by the presence of severely tortuous coronary arteries. In the control group, 1 patient was lost to follow-up, and 2 were excluded because of insufficient IVUS images. Consequently, 46 patients completed the study (22 patients in the pioglitazone treatment group, 24 patients in the control group). A total of 42 lesions (1.1±0.3 lesions per vessel) in the pioglitazone group and 44 lesions (1.1±0.3 lesions per vessel) in the control group were examined with VH-IVUS. Baseline characteristics of the study subjects are shown in Table 1 . There were no significant differences between the 2 groups with regard to sex, body mass index, coronary risk factors, or in the use of concomitant medications. Throughout the study, pioglitazone was well tolerated by all patients in the pioglitazone group. Leg edema occurred in 2 patients in the pioglitazone group, but it was transient and resolved spontaneously.
Quantitative Morphologic IVUS analysis
Baseline lesion characteristics and quantitative morphologic IVUS analysis of target plaque are shown in Table 2 . There were no significant differences in the lesion characteristics of the 2 groups, nor in any of the morphologic parameters. Table 3 shows the laboratory results at baseline and at the 6-month follow-up for the 2 groups. There were no significant differences between them for any of the biomarkers at baseline. Intra-group comparisons revealed that in the pioglitazone group the HDL-cholesterol and plasma adiponectin levels were significantly increased, and the LDL-cholesterol, fasting glucose, HbA1c, IRI, HOMA-IR and hsCRP levels were significantly decreased, whereas only the HDL-cholesterol levels were increased in the control group. Inter-group comparisons at 6 months revealed that patients in the pioglitazone group had significantly lower fasting glucose, IRI, and HOMA-IR levels and significantly higher plasma adiponectin levels than patients in the control group. As for the absolute change from baseline during the 6-month follow-up period, the pioglitazone group had significantly decreased fasting glucose, HbA1c, IRI, and HOMA-IR levels, and significantly increased plasma adiponectin levels, in comparison with the control group.
Laboratory Results
VH-IVUS Analysis
The histologic parameters of the 2 groups detected by VH-IVUS analysis at baseline and 6-month follow-up are summarized in Table 4 . At baseline, there were no significant differences between the 2 groups in absolute and %-Plaque volume, nor in any of the plaque components. At the 6-month follow-up, there was no change in absolute or 
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%-Plaque volume in either group. For the plaque components in the pioglitazone group, there was an increase in %Fibrous, absolute Fibro-fatty, and %Fibro-fatty, and a decrease in %Dense-calcium, absolute Necrotic-core, and %Necrotic-core. As for the change from baseline during the 6-month follow-up period, %Fibrous and %Fibro-fatty significantly increased, and %Dense-calcium and %Necrotic-core significantly decreased in the pioglitazone group compared with the control group, but there was no significant change in any of the absolute data. The individual change in the %Necrotic-core of each plaque is shown in Fig 3 .
Correlation Between the Change in Adiponectin Level and Each Plaque Component
Because pioglitazone therapy resulted in a roughly doubling of the plasma adiponectin level, we further analyzed the correlation between the absolute change in plasma adiponectin level and the absolute change in the ratios of the plaque components (n=86; Fig 4) . The change in plasma adiponectin level was significantly positively correlated with the changes in %Fibrous (r=0.23; P=0.03, Fig 4A) and %Fibro-fatty (r=0.41; P<0.0001, Fig 4B) , and was significantly negatively correlated with the changes in %Dense-calcium (r=-0.34; P=0.002, Fig 4C) and %Necrotic-core (r=-0.46; P<0.0001, Fig 4D) . In contrast, there were no significant correlations between the changes in any of the plaque components and the changes in any of the other biomarkers examined in the present study.
Discussion
The findings of the present study demonstrate that pioglitazone treatment improved insulin sensitivity, increased plasma adiponectin levels, and tended to decrease hs-CRP levels. Binary VH-IVUS analysis revealed that pioglitazone reduced the necrotic-core component, and the increase in plasma adiponectin level correlated with a reduced necroticcore component. These findings indicate that pioglitazone may stabilize the coronary plaque contents (derived from the VH-IVUS analysis), in part by increasing the plasma adiponectin level.
As for the treatment of DM, until now there has not been evidence that any antidiabetic treatment, except for pioglitazone used in the PROactive study, can reduce macrovascular events. 9 Pioglitazone, which is an oral insulin sensitizer of the PPARγ agonist, is commercially available for the treatment of insulin resistance and type 2 DM. In addition to its blood glucose lowering and insulin resistance reducing properties, pioglitazone also has an anti-atherogenic effect. The CHICAGO Trial showed that, compared with glimepiride, pioglitazone slowed down the progression of carotid intima -media thickness in vivo. 15 Furthermore in the PERISCOPE Trial, treatment with pioglitazone resulted in a significant reduction in the percent atheroma volume compared with glimepiride on serial IVUS examination. 10 Other studies have also revealed that pioglitazone attenuates neointimal tissue proliferation after coronary stent implantation in patients with and without DM. 16, 17 These findings suggest that the anti-atherogenic effect of pioglitazone is independent of its effect on glycemic control, and we hypothesize that it is partially attributable to the effect of pioglitazone on the plasma adiponectin level.
Adiponectin is an adipocyte-derived plasma protein that is the most abundant adipocytokine in the circulation and is produced by visceral fat cells. 18 Adiponectin inhibits the endothelial expression of adhesion molecules, 19 and suppresses vascular smooth muscle cell proliferation. 20 Furthermore, Okamoto et al reported that an adenovirus-mediated increase of adiponectin significantly suppressed the progression of atherosclerotic lesions in apoE -/-mice, and further reported that overexpression of adiponectin could actually reduce atherosclerosis by attenuating the endothelial inflammatory response and macrophage-to-foam cell transformation. 6 Accumulating evidence indicates that plasma adiponectin levels are reduced in patients with CAD. 5, 19, 21 Further, plasma adiponectin levels in patients with acute coronary syndrome (ACS) are significantly lower than those in patients with stable CAD. 8 We reported an inverse relationship between the plasma adiponectin level and necrotic-core volume detected by VH-IVUS in culprit and non-culprit lesions in patients with ACS. 22 Low levels of adiponectin are associated with not only a high incidence of CAD events, but also the development of ACS, and these findings led us to propose that pharmaceutical therapy with the aim of increasing adiponectin is important for preventing macrovascular events. Thiazolidinedione derivatives enhance adiponectin mRNA expression, 23 and increase the number of newly differentiated small adipocytes through PPARγ activation, 24 which leads to increased adiponectin levels. Many investigators have demonstrated that pioglitazone markedly increases adiponectin secretion in normal, obese, and type 2 DM subjects. 11, 25 In agreement with those studies, treatment with pioglitazone approximately doubled the plasma adiponectin levels in the present study.
Vulnerable plaque, which may be a predisposing factor for ACS, is frequently located in coronary segments without significant narrowing, thus making it undetectable by angiography. 26 Gray-scale IVUS is the gold standard for evaluating atherosclerotic plaque in vivo, because conventional IVUS interpretation has several drawbacks for detailed evaluation of plaque components; notably, it cannot reliably discriminate lipid-rich plaque from fibrous plaque. 27 To overcome this problem, spectral analysis of IVUS radiofrequency data was recently developed and VH-IVUS seems to have potential for real-time assessment of plaque morphology, and can be practically used in the clinical setting. Furthermore, VH-IVUS provides quantitative information about the atherosclerotic burden or activity associated with its progression and even its regression. These developments have resulted in the ability of VH-IVUS to be used for precise evaluation of long-term and pharmaceutical effects on coronary plaque. 28 In the present, preliminary study, the reproducibility of VH-IVUS was comparable to that in a previous report. 29 We observed that pioglitazone treatment noticeably reduced the necrotic-core component, which is thought to consist of a lipid core with remnants of foam cells, cholesterol clefts, micro-calcium and dense macrophages, as detected by VH-IVUS, [12] [13] [14] and may be closely related to vulnerable plaque. Garcia et al also reported that the necrotic-core content was significantly correlated with plaque size in patients with ACS. 30 Thus, a reduction of the necrotic-core area may be linked to plaque stabilization, leading to a reduction in the incidence of ACS. In the present VH-IVUS analysis, a change in the plasma adiponectin level correlated with a change in each plaque component examined and of these, we draw special attention to the fact that a reduction in the necrotic-core area correlated with an increase in plasma adiponectin level. Ouchi et al demonstrated that adiponectin treatment dose-dependently suppressed tumor necrosis factor-α-induced monocyte adhesion and inhibited expression of class A macrophage scavenger receptors, which have an important role in the uptake of modified LDL. 19, 31 Our clinical finding is consistent with the results of those in vitro studies, which leads us to speculate that adiponectin may be involved in regulating the development of the necrotic-core, and thus be associated with plaque vulnerabili ty. Moreover, despite the lack of a change in the total plaque volume in the present study, treatment with pioglitazone significantly reduced the %Necrotic-core and increased the %Fibro-fatty and %Fibrous. We also postulate that a relatively small dose of pioglitazone might enhance the plasma adiponectin level and decrease the size of necrotic-core, even if an actual reduction in coronary plaque volume is not achieved. In addition, a reduction in the necrotic-core area may contribute to an increase in the fibro-fatty or fibrous area, which may be a possible process of plaque stabilization. The actual mechanism of plaque stabilization, however, is still unclear. Furthermore, whether plaque characterization, determined with VH-IVUS according to clinical presentation, relates to plaque vulnerability remains controversial. Further studies to examine these issues are necessary.
Study Limitations
There are some limitations to the study that might affect interpretation of the data. First, the study was a single-center, pilot study with a small number of patients. As shown in Fig 3 , not all lesions in the pioglitazone group achieved a significant reduction in the necrotic-core as assessed by VH-IVUS examination, and we could not evaluate which lesions were more susceptible to pioglitazone therapy with this small sample size. Further validation with a larger population and longer follow-up period is required to clarify our results. Second, this study did not directly assess coronary plaque. Although VH-IVUS is a promising diagnostic tool for visual interpretation of plaque characterization, it is only a substitute for histopathologic sampling. Atherosclerotic plaque is essentially heterogeneous, but the VH-IVUS algorithm forcibly assigns coronary plaque into 4 types according to the homogeneity of certain regions. Nair et al reported that dividing plaque into 4 distinct tissue components is difficult because of amorphous overlapping zones. 14 They further described that a borderline spectral pattern exists between the Necrotic-core and the Dense-calcium area in VH-IVUS tissue identification because these components are adjacent on the VH-IVUS classification tree. In our study, a minor reduction in %Dense-calcium was detected in the pioglitazone group. Part of that reduction may involve a decrease in the borderline spectrum of the adjacent Necrotic-core area. Furthermore, because of attenuation of the IVUS backscattered signal, the accuracy of VH-IVUS tissue identification tends to deteriorate, especially in the acoustic shadow area behind a severe calcification arc. Therefore, there are some potential limitations for the classification of Dense-calcium by VH-IVUS analysis, and this issue must be further examined. Third, we could only examine PCI-related vessels and analyzed merely non-culprit, moderate obstructive lesions. Our study results are not representative of the whole coronary artery, which may therefore include some bias.
Conclusion
To the best of our knowledge, this is the first pilot study to suggest the potential of pioglitazone therapy for ameliorating coronary plaque content, and a link between changes in coronary plaque components based on VH-IVUS analysis and changes in plasma adiponectin levels. In conclusion, pioglitazone treatment of patients with type 2 DM significantly increased their plasma adiponectin levels, and VH-IVUS analysis indicated that this increase was associated with a reduction in the coronary plaque necrotic-core component, which may be a possible mechanism for the prevention of macrovascular events.
Disclosure
None.
